Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    Giroptic makes a splash with Facebook

    At Facebook’s annual conference in California, an enthusiastic Mark Zuckerberg gave a Giroptic iO camera to every attendee—and wrote a $1 million check to the Lille-based start-up.

    Arcelor Mittal Dunkerque investing in performance

    Steelmaker earmarks €31 million for continuous hot mill at Dunkerque plant.

    All news

    EGID exemplifies excellence of research “Made in Lille Region”

    24 Oct 2014 | A region on the move, Health Nutrition

    EGID lays the first stone of a new diabetes research center, stepping up the pace of progress in Northern France—already a frontrunner in fighting this debilitating disease.

    EGID - Lille Region

    France’s 1st Institute for diabetes and obesity research

    Founded in 2009, the European Genomic Institute for Diabetes (EGID) is France’s premier research body dedicated to diabetes and its complications.
    The institute’s primary mission is to prevent the onset of this debilitating disease and provide better patient treatment by identifying risk factors and reaching a better understanding of the mechanisms that cause diabetic complications.
    Scheduled to open in 2016, the new facility is located at the heart of Lille’s university hospital campus in a building that will include both high-tech platforms and a project center.

    Local roots, local applications

    With one of the highest rates of diabetes in France, Lille Region is dedicated to fighting the disease and improving patient care. It is also home to three of the world’s top diabetes research teams, who founded EGID to pool existing local expertise immediately and work together more effectively to advance the project’s scientific agenda.
    The complementary, internationally recognized expertise of these founding research teams was critical in making EGID a reality. Headed by Philippe Froguel of the Genomics and Metabolic illnesses lab, François Pattou of the Biotherapy and Diabetes lab, and Bart Staels of the Nuclear Receptors, Cardiovascular Disease and Atherosclerosis lab, all three Lille-based teams are exploring new and very concrete options in diabetes research.

    3 major breakthroughs resulting from EGID research to date:

    • Personalized therapies bring blood glucose levels back to normal in diabetic children 
    • Pancreatic cell transplants reduce neurological complications and increase life expectancy
    • New medications improve treatment for diabetics, in particular those suffering from heart conditions.

    Interested? EGID is organizing its third symposium at Lille’s IDEA Summit, hosted by BioFIT 2014 on December 2-3. Learn more.

     

    Source: La Voix du Nord, egid.fr

     

     

    Back to news